Antibody-Drug Conjugate, ADC:

Market Insight, CDMO Pricing and Competitor Benchmarking

Over 700 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Antibody–Drug Conjugate, ADC: Market Insight, CDMO Pricing and Competitor Benchmarking study.

About This Report

• In our first antibody–drug conjugate (ADC) report, we explore the manufacturing challenges, clinical trial landscape, and benchmark batch pricing for this new modality of therapeutics.

• We have built a proprietary data analysis tool to analyze the state of clinical trials ongoing and completed in the U.S.

• We evaluate trends in different payloads, trial size, and trial durations, along with top sponsors and top indications being studied.

• We provide projections for ongoing growth of therapeutics entering the clinic and expecting approval, which will drive the need for manufacturing and analytical services.

• We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.

• We spoke with subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.

• We put the manufacturing market in context of ongoing geopolitical news.

Study Methodology

• For the first edition of Nice Insight’s Antibody–Drug Conjugate, ADC: Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused on the rapidly expanding ADC market. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development tool evaluating manufacturing of biologics in mammalian cells. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.

• To build and analyze a dataset of ADC clinical trials, we created a proprietary search tool that uses the trials published at ClinicalTrials.gov since January 1, 2013. We probed the dataset in multiple queries to pull out all clinical trials, including building custom macros to mine the data based on drug name, modality, and keywords. We then carefully curated and cleaned the dataset for use in our analysis.

• The data from 1,613 trials posted as of June 13, 2024, were curated to focus only on the investigation of ADC antibodies, separating them from classical monoclonal antibodies. This dataset was used to analyze innovators, funding, modalities, and more.

• The content included here reflects in total over 700 hours of dedicated research, interviews, analysis, and composition, both to develop the 2024 pricing study and survey of clinical trials published.

• A team comprising six Ph.D.-level experts collaborated with a group of 10+ SMEs within the ADC manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.

• Our staff with over 80 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.

• Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.